Therapeutic Immunosuppression and Drug-Induced Immunodeficiency

Therapeutic immunosuppression is the deliberate pharmacological dampening of immune responses, used to prevent transplant rejection and to control autoimmune and inflammatory disease. Because it blunts the same defences that protect against infection, immunosuppressive therapy is also the leading iatrogenic cause of secondary immunodeficiency, creating a trade-off between controlling unwanted immunity and preserving host defence.

Definition

Therapeutic immunosuppression is the intentional reduction of immune-system activity by drugs or other interventions, applied in transplantation and immune-mediated disease. Drug-induced immunodeficiency is the resulting secondary immunodeficiency, in which suppression of immune effector function increases susceptibility to infection and, with some agents, to malignancy.

Scope

The entry frames immunosuppression as both a therapeutic strategy and a recognised cause of drug-induced immunodeficiency. It surveys the principal mechanistic classes of immunosuppressive agents and the concept of net state of immunosuppression, situating drug-induced immune failure within the broader category of secondary immunodeficiency, as a reference rather than prescriptive guidance.

Core questions

• By what mechanisms do the major classes of immunosuppressive drug reduce immune responses?
• How does therapeutic immunosuppression become a cause of secondary immunodeficiency?
• What is meant by the 'net state of immunosuppression' and the trade-off it represents?

Key concepts

• Calcineurin inhibitors
• Antiproliferative agents
• Corticosteroids
• mTOR inhibitors
• Biologic and monoclonal-antibody immunosuppressants
• Net state of immunosuppression
• Opportunistic infection risk
• Iatrogenic (drug-induced) immunodeficiency
• Transplant rejection prevention

Mechanisms

Immunosuppressive agents act at distinct points of the immune response. Corticosteroids broadly suppress inflammatory gene expression and lymphocyte function; calcineurin inhibitors block the signalling pathway that drives T-cell cytokine production; antiproliferative agents inhibit the nucleotide synthesis that dividing lymphocytes require; mTOR inhibitors interrupt lymphocyte proliferation signals; and biologic agents target specific cytokines, surface molecules, or cell populations (Halloran, 2004; Allison, 2000). Each blunts a portion of immune function, and their combined effect determines a patient's overall vulnerability, often summarised as the net state of immunosuppression. Because the same effector arms defend against pathogens, the predictable cost is increased susceptibility to opportunistic and reactivating infections, placing drug-induced immunodeficiency conceptually alongside other acquired immunodeficiencies such as HIV (Deeks, 2015).

Clinical relevance

Understanding which immune pathway a given agent suppresses underpins how the infection risks of immunosuppression are conceptualised, and the net-state-of-immunosuppression idea captures why combinations matter more than any single drug. As a reference topic this entry describes mechanisms and trade-offs at a conceptual level; it gives no dosing, regimen, or individualised treatment advice.

Epidemiology

Therapeutic immunosuppression is used widely across solid-organ and stem-cell transplantation and across autoimmune and inflammatory diseases, making drug-induced immunodeficiency one of the most common forms of secondary immune failure in high-income health systems. The associated infection and, for some agents, malignancy risks are well recognised as the principal cost of these therapies (Halloran, 2004; Allison, 2000).

Evidence & guidelines

Reviews of transplantation immunosuppression describe the mechanistic classes and their consequences (Halloran, 2004), and a historical synthesis traces the development of immunosuppressive pharmacology (Allison, 2000). The framing of drug-induced immunodeficiency as a secondary immunodeficiency draws on the broader acquired-immunodeficiency literature (Deeks, 2015).

History

Modern transplantation became feasible only with the advent of immunosuppressive drugs, beginning with corticosteroids and azathioprine and transformed in the late twentieth century by the introduction of cyclosporine and later calcineurin inhibitors. Successive classes broadened the ability to control unwanted immunity, while clinical experience made clear that the price of suppression is heightened susceptibility to infection, defining drug-induced immunodeficiency as a distinct entity (Allison, 2000; Halloran, 2004).

Key figures

• Philip Halloran
• Anthony Allison
• Jean Borel

Seminal works

• halloran-2004
• allison-2000
• deeks-2015

Frequently asked questions

How can a medicine cause immunodeficiency?

Immunosuppressive drugs deliberately reduce immune activity to control transplant rejection or autoimmune disease, but the same suppression weakens defence against pathogens, so a recognised side effect is an acquired (drug-induced) immunodeficiency with increased susceptibility to infection.

What is the 'net state of immunosuppression'?

It is a conceptual summary of a patient's overall vulnerability to infection arising from the combined effect of all immunosuppressive influences, recognising that the total burden, rather than any single drug, determines the risk.